Kiniksa Pharmaceuticals Market Sentiment

Kiniksa Pharmaceuticals International PLC

KNSANASDAQ

Trade with Public

$79.87

0.841.07%

Last update: Aug 24, 12:44 PM

Overview News Earnings Forecast Events Price Targets FinancialsSentimentOwnership Compare Options Stock Report

Kiniksa Pharmaceuticals Market Sentiment

Market sentiment signals for Kiniksa Pharmaceuticals (KNSA): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▲ 10.8% short float

Options Flow▲ 0.02 P/C ratio

Insider Activity▼ Net Seller (30d)

Analyst Consensus

Buy

9 analysts

Options Flow (P/C)

0.02

More calls — Bullish

846 calls · 17 puts

Avg Consensus PT

$82

+2.1%

Highest Price Target

$107

+34.0%

JP Morgan

Lowest Price Target

$35

-56.2%

Evercore ISI Group

Short Interest

10.8%

Declining — Bullish

Insider Activity (30d)

Net Seller

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Jul 30, 2026	Goldman Sachs	Paul Choi—	+12.7%	$75 → $90	Maintained	Buy
Jul 29, 2026	JP Morgan	Anupam Rama—	+34.0%	$72 → $107	Maintained	Overweight
Jul 29, 2026	Canaccord Genuity	Edward Nash—	+22.7%	$64 → $98	Maintained	Buy
Jul 29, 2026	Wedbush	David Nierengarten—	+23.9%	$72 → $99	Maintained	Outperform
Jul 29, 2026	Citigroup	Geoff Meacham—	+25.2%	$60 → $100	Maintained	Buy
Jul 23, 2026	Goldman Sachs	Paul Choi—	-6.1%	$60 → $75	Maintained	Buy
Jul 13, 2026	Wells Fargo	Eva Fortea Verdejo—	-7.4%	$57 → $74	Maintained	Overweight
Jun 29, 2026	Wedbush	David Nierengarten—	-9.9%	$59 → $72	Maintained	Outperform
Apr 29, 2026	Canaccord Genuity	Edward Nash—	-19.9%	$62 → $64	Maintained	Buy
Apr 29, 2026	Citigroup	Geoff Meacham—	-24.9%	$50 → $60	Maintained	Buy
Apr 29, 2026	Wedbush	David Nierengarten—	-26.1%	$58 → $59	Maintained	Outperform
Apr 29, 2026	Wells Fargo	Eva Fortea Verdejo—	-28.6%	$53 → $57	Maintained	Overweight
Apr 28, 2026	Jefferies	Roger Song—	-11.1%	$58 → $71	Maintained	Buy
Apr 16, 2026	Wedbush	David Nierengarten—	-27.4%	$53 → $58	Maintained	Outperform
Feb 25, 2026	Wells Fargo	Eva Fortea Verdejo—	-33.6%	$50 → $53	Maintained	Overweight
Feb 25, 2026	Wedbush	David Nierengarten—	-33.6%	$50 → $53	Maintained	Outperform
Feb 19, 2026	Canaccord Genuity	Edward Nash—	-22.4%	$62	Initiate	Buy
Jan 13, 2026	Wedbush	David Nierengarten—	-37.4%	$48 → $50	Maintained	Outperform
Oct 29, 2025	Goldman Sachs	Paul Choi—	-31.1%	$45 → $55	Maintained	Buy
Oct 17, 2025	Citigroup	Geoff Meacham—	-37.4%	$45 → $50	Maintained	Buy
Oct 13, 2025	Wedbush	David Nierengarten—	-44.9%	$38 → $44	Maintained	Outperform
Sep 29, 2025	TD Cowen	Nicholas Lorusso—	-24.9%	$60	Initiate	Buy
Sep 25, 2025	Wells Fargo	Eva Fortea Verdejo—	-43.7%	$42 → $45	Maintained	Overweight
Jul 29, 2025	Jefferies	Roger Song—	-32.4%	$45 → $54	Maintained	Buy
Jul 9, 2025	Wells Fargo	Eva Fortea Verdejo—	-47.4%	$30 → $42	Maintained	Overweight